Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVB: Adalimumab vs Tocilizumab in Severe Uveitis of Behçet’s Disease
2024-513371-41-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in uveitis and Behçet's disease (BD) comparing Humira with RoActemra (2 arms). Planned start Aug 2024; status: authorised.
02
Drugs
adalimumabtocilizumab
03
Conditions
uveitisBehçet's disease (BD)
Beyond the preview
Go deeper on 2024-513371-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513371-41-00.